Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polymerized grass pollen allergenic extract is a subcutaneous allergen immunotherapy (SCIT) product developed by Inmunotek. The active ingredient consists of polymerized allergenic extracts derived from grass pollen species (primarily *Phleum pratense* and *Dactylis glomerata*), which are chemically modified (polymerized) using glutaraldehyde to reduce IgE-mediated allergenicity while retaining immunogenicity. This modification allows for a safer and more rapid up-dosing schedule. The drug is indicated for the treatment of grass pollen allergy, allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma in sensitized patients. It is marketed under brand names such as ALXOID and CLUSTOID.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polymerized grass pollen allergenic extract.